Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Legoux

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 5, 2020
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III studySylvain Manfredi, Anthony Turpin, David Malka, et al.
Gut|October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
Gastroenterologie Clinique Et Biologique|November 1, 2006
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]Jean-Louis Legoux, Laurent Bedenne, Jean-François Seitz, et al.
Gastroenterologie Clinique Et Biologique|September 6, 2005
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine GastroYves Bécouarn, Anne Rullier, Philippe Gorry, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive OncologyElodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Clinics and Research in Hepatology and Gastroenterology|March 22, 2021
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 studyJean-Louis Legoux, Catherine Lombard-Bohas, Hedia Brixi, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
Neuroendocrinology|February 3, 2017
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 5, 2020
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III studySylvain Manfredi, Anthony Turpin, David Malka, et al.
Gut|October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
Gastroenterologie Clinique Et Biologique|November 1, 2006
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]Jean-Louis Legoux, Laurent Bedenne, Jean-François Seitz, et al.
Gastroenterologie Clinique Et Biologique|September 6, 2005
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine GastroYves Bécouarn, Anne Rullier, Philippe Gorry, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive OncologyElodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Clinics and Research in Hepatology and Gastroenterology|March 22, 2021
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 studyJean-Louis Legoux, Catherine Lombard-Bohas, Hedia Brixi, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
Neuroendocrinology|February 3, 2017
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, et al.
Pageof 4